Stockreport

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF It was a moderately negative result overall - revenue fell 8.4% short of analyst estimates at US$21m, and statutory losses were in line with analyst expectations, at US$ [Read more]